Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, FRACP,MBBS,MSc,FRCPA, John Reynolds, PhD, Wojt Janowski, FRCPA,FRACP, Hang Quach, MDFRACP,FRCPA,MBBS, Philip Campbell, MBBS, Simon D. Gibbs, FRACP, FRCPA, MBBS, Sophie Lee, FRACP, FRCPA, PhD, James D'Rozario, MBBS, FRACP, FRCPA, Kerry Taylor, FRACP,FRCPA,MBBS, Tara Cochrane, MBBS,FRCPA,FRACP, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Fiona Kwok, FRACP,FRCPA,MBBS, Nicholas Weber, MBBS, Ian H. Kerridge, FRACP FRCPA MPhil BA, Helen Weston, MBBS, FRACP, FRCPA, Phoebe Joy Ho, MBBS,DPhil,FRACP,FRCPA, Noemi Horvath, MB ChB FRACP FRCPA, Flora Yuen, BBiomedSc, Andrew Spencer

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138394

Published: 2020

Journal Articles

The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Phoebe Joy Ho, MBBS,DPhil,FRACP,FRCPA, Elizabeth M. Moore, PhD, Cameron Wellard, Hang Quach, MD, Hilary Blacklock, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Emma-Jane McDonald, MRCP, FRCPath, Zoe McQuilten, MBBS, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Peter Mollee, FRACP,MBBS,MSc,FRCPA, Andrew Spencer

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141511

Published: 2020

Journal Articles

Bing Neel Syndrome: Retrospective Australasian Experience of a Rare Treatable Complication of Waldenström Macroglobulinaemia/ Lymphoplasmacytic Lymphoma

Dipti Talaulikar, PhD FRACP, FRCPA, MBBS, Tara Cochrane, MBBS, John Gibson, Nada Hamad, MBBS, BSc, MSc, Phoebe Joy Ho, MBBS DPhil FRACP FRCPA, Samar Issa, FRACP, Kwok Fiona, Jun Hee Lim, PhD, David Simpson, MBChB, FRACP, FRCPA, Constantine Tam, MD PhD, Jorge J. Castillo, MD

Blood (2018) 132 (Supplement 1): 5325.

https://doi.org/10.1182/blood-2018-99-113969

Published: 2018

Journal Articles

Early Serum Free Light Chain (SFLC) Kinetics Is Highly Predictive of Renal Response in Carfilzomib/ Dexamethasone (Cfz/Dex) in Myeloma (MM) Patients with Renal Impairment (RI) — Interim Analysis of the Australian ALLG MM16 Trial

Phoebe Joy Ho, MBBS DPhil FRACP FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, Anoop K Enjeti, MBBS, FRCPA, MD MRCP, Noemi Horvath, MBBS FRACP FRCPA, Christian E Bryant, MBBS, PhD FRACP, FRCPA, Judith Trotman, Simon Gibbs, FRACP, FRCPA, MBBS, Douglas E Joshua, BSc(Hons) MBBS DPhil FRACP FRCPA

Blood (2018) 132 (Supplement 1): 3283.

https://doi.org/10.1182/blood-2018-99-110664

Published: 2018

Journal Articles

Pomalidomide Alone or in Combination with Low Dose Dexamethasone As Maintenance Following Induction with Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (ALLG MM14)

Anna Kalff, MBBS, Nola Kennedy, John Reynolds, PhD, Hang Quach, MDFRACP,FRCPA,MBBS, Phoebe Joy Ho, MBBS, Noemi Horvath, MBBS FRACP FRCPA, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, James M. D'Rozario, MBBS, FRACP, FRCPA, Kerry Taylor, FRACP,FRCPA,MBBS, Jane Estell, FRACP, Andrew Spencer, MBBS, MD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 1986.

https://doi.org/10.1182/blood-2018-99-118231

Published: 2018

Journal Articles

A Blood Dendritic Cell Vaccine for Acute Myeloid Leukemia

Jennifer Hsu, PhD, Christian Bryant, Phillip Fromm, PhD, Michael Papadimitrious, Daniel Orellana, Hayley Suen, Shihong Yang, Claire Weatherburn, Robin Gasiorowski, Harry J Iland, MBBS FRACP FRCPA, Ross D Brown, Douglas E Joshua, Phoebe Joy Ho, MBBS, DPhil, John Gibson, Georgina Clark, Derek NJ Hart

Blood (2016) 128 (22): 5221.

https://doi.org/10.1182/blood.V128.22.5221.5221

Published: 2016

Journal Articles

Blockade of the Hedgehog Signaling Pathway by the Novel Agent NVP-LDE225 Induces Differentiation, Prevents De-Differentiation and Inhibits Proliferation of Multiple Myeloma Stem Cells in Vitro

Shihong Yang, MSc, Ross D Brown, PhD, Yen S Loh, PhD, Hayley Suen, BSc (Hons), James Favaloro, BSc, John Gibson, MBBS, PhD, Phoebe Joy Ho, MBBS, DPhil, Douglas E Joshua, MBBS, DPhil

Blood (2012) 120 (21): 3950.

https://doi.org/10.1182/blood.V120.21.3950.3950

Published: 2012

Journal Articles

Bim Is Required to Sensitize Mantle Cell Lymphoma Cells for Killing by Bortezomib, but Not Ara-C, by Selective Inhibition of CDK4/CDK6

Xiangao Huang, PhD, Maurizio Di Liberto, Ph.D., Jamieson Bretz, Ph.D., David Chiron, PhD, Peter Martin, MD, Morton Coleman, MD, Jia Ruan, MD, PhD, Mitchell R Smith, MD, PhD, Scott A Ely, M.D., Christopher E. Mason, PhD, Phoebe Joy Ho, MBBS, DPhil, John P. Leonard, MD, Selina Chen-Kiang, PhD

Blood (2011) 118 (21): 1655.

https://doi.org/10.1182/blood.V118.21.1655.1655

Published: 2011

Journal Articles

Safety and Efficacy of CEEP (Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) with or without Rituximab in Elderly Patients (>70) with Diffuse Large B-Cell Lymphoma (DLBL): A Retrospective Single Center Experience

Danny Hsu, MBBS FRACP FRCPA, Ibrahim Tohidi-Esfahani, MBBS, Christina Brown, MBBS PhD FRACP FRCPA, Scott Dunkley, MBBS FRACP FRCPA, Stephen Robert Larsen, MBBS FRACP FRCPA PhD, Phoebe Joy Ho, MBBS FRCPA FRACP DPhil, Harry Iland, MBBS FRACP FRCPA MHGSA, John Gibson, MBBS FRACP FRCPA DPhil, Douglas E. Joshua, MBBS DPhil FRACP FRCPA AM

Blood (2011) 118 (21): 4957.

https://doi.org/10.1182/blood.V118.21.4957.4957

Published: 2011

Journal Articles

HLA-G and CD86 Expression on Malignant Plasma Cells Convey a Poor Prognosis and Immunoregulate T Cells In Patients with Myeloma

Ross D. Brown, PhD, Karieshma Kabani, Shihong Yang, Esther Aklilu, Phoebe Joy Ho, MBBS, John Gibson, MBBS, Douglas E. Joshua, MBBS, DPhil

Blood (2010) 116 (21): 983.

https://doi.org/10.1182/blood.V116.21.983.983

Published: 2010

Journal Articles

Trogocytosis in Multiple Myeloma.

Ross D. Brown, PhD, MBA, Karieshma Kabani, BSc, Shihong Yang, MSc, Aklilu Esther, BSc, Phoebe Joy Ho, MBBS, DPhil, John Gibson, MBBS, PhD, Douglas E. Joshua, MBBS, DPhil

Blood (2008) 112 (11): 1681.

https://doi.org/10.1182/blood.V112.11.1681.1681

Published: 2008

Journal Articles

Characterization of Bortezomib Resistance in Multiple Myeloma Cell Lines

Silvia CW Ling, MBBS, FRCPA, FRACP, Angela M Nikolic, BSc, Ammira Al-Shabeeb, BVM, MSc, PhD, Edwin Lau, BSc, Phoebe Joy Ho, MBBS, FRCPA, FRACP, DPhil, Douglas Joshua, BSc, MBBS(Sydney), DPhil(Oxon), John D Allen, BSc, PhD

Blood (2008) 112 (11): 2639.

https://doi.org/10.1182/blood.V112.11.2639.2639

Published: 2008

NARROW

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Bing Neel Syndrome: Retrospective Australasian Experience of a Rare Treatable Complication of Waldenström Macroglobulinaemia/ Lymphoplasmacytic Lymphoma

Early Serum Free Light Chain (SFLC) Kinetics Is Highly Predictive of Renal Response in Carfilzomib/ Dexamethasone (Cfz/Dex) in Myeloma (MM) Patients with Renal Impairment (RI) — Interim Analysis of the Australian ALLG MM16 Trial

Pomalidomide Alone or in Combination with Low Dose Dexamethasone As Maintenance Following Induction with Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (ALLG MM14)

A Blood Dendritic Cell Vaccine for Acute Myeloid Leukemia

Blockade of the Hedgehog Signaling Pathway by the Novel Agent NVP-LDE225 Induces Differentiation, Prevents De-Differentiation and Inhibits Proliferation of Multiple Myeloma Stem Cells in Vitro

Bim Is Required to Sensitize Mantle Cell Lymphoma Cells for Killing by Bortezomib, but Not Ara-C, by Selective Inhibition of CDK4/CDK6

Safety and Efficacy of CEEP (Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) with or without Rituximab in Elderly Patients (>70) with Diffuse Large B-Cell Lymphoma (DLBL): A Retrospective Single Center Experience

HLA-G and CD86 Expression on Malignant Plasma Cells Convey a Poor Prognosis and Immunoregulate T Cells In Patients with Myeloma

Trogocytosis in Multiple Myeloma.

Characterization of Bortezomib Resistance in Multiple Myeloma Cell Lines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only